Dna Biomed Solns Stock Fundamentals
| DNA Stock | ILS 86.90 0.20 0.23% |
DNA Biomed Solns fundamentals help investors to digest information that contributes to DNA Biomed's financial success or failures. It also enables traders to predict the movement of DNA Stock. The fundamental analysis module provides a way to measure DNA Biomed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNA Biomed stock.
DNA |
DNA Biomed Solns Company Shares Outstanding Analysis
DNA Biomed's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current DNA Biomed Shares Outstanding | 123.16 M |
Most of DNA Biomed's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNA Biomed Solns is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, DNA Biomed Solns has 123.16 M of shares currently outstending. This is 31.78% lower than that of the Electronic Equipment, Instruments & Components sector and 15.26% higher than that of the Information Technology industry. The shares outstanding for all Israel stocks is 78.46% higher than that of the company.
DNA Biomed Solns Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DNA Biomed's current stock value. Our valuation model uses many indicators to compare DNA Biomed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DNA Biomed competition to find correlations between indicators driving DNA Biomed's intrinsic value. More Info.DNA Biomed Solns is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value DNA Biomed by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DNA Biomed's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.DNA Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNA Biomed's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNA Biomed could also be used in its relative valuation, which is a method of valuing DNA Biomed by comparing valuation metrics of similar companies.DNA Biomed is currently under evaluation in shares outstanding category among its peers.
DNA Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0375 | |||
| Current Valuation | 59.57 M | |||
| Shares Outstanding | 123.16 M | |||
| Shares Owned By Insiders | 54.87 % | |||
| Price To Earning | 22.59 X | |||
| Price To Book | 0.95 X | |||
| EBITDA | 18.42 M | |||
| Net Income | 18.37 M | |||
| Cash And Equivalents | 492 K | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | 0.79 X | |||
| Cash Flow From Operations | (2.33 M) | |||
| Earnings Per Share | 0.21 X | |||
| Number Of Employees | 11 | |||
| Beta | 0.31 | |||
| Market Capitalization | 86.46 M | |||
| Total Asset | 54.62 M | |||
| Retained Earnings | (139 M) | |||
| Working Capital | 18 M | |||
| Current Asset | 26 M | |||
| Current Liabilities | 8 M | |||
| Z Score | -2.8 | |||
| Net Asset | 54.62 M |
About DNA Biomed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DNA Biomed Solns's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNA Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNA Biomed Solns based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel. D N operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DNA Stock
DNA Biomed financial ratios help investors to determine whether DNA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DNA with respect to the benefits of owning DNA Biomed security.